Key result
Reactive ATP is linked to a ~53% lower incidence of persistent AF versus DDDR pacing.
Why the study?
It was unclear whether Reactive ATP alone, independent of preventive pacing, is the main driver of persistent or permanent AF reduction observed with DDDRP pacing in pacemaker patients with an AF history.
Does Reactive ATP without preventive pacing reduce the incidence of persistent AF in dual-chamber pacemaker patients with a history of AF?
Observational (n=146)
Yes
Does Reactive ATP without preventive pacing reduce the incidence of persistent AF in dual-chamber pacemaker patients with a history of AF?
Reactive ATP alone is associated with a low incidence of persistent AF in pacemaker patients, suggesting it is the primary driver of the benefits observed in the MINERVA trial.
Answers are grounded in this paper and cite their sources.
Reactive ATP alone may reduce persistent AF incidence in pacemaker patients; leaves open confirmation versus full algorithm combinations in randomized trials.
OBJECTIVE: The MINERVA trial showed that in pacemaker patients with atrial fibrillation (AF) history, DDDRP pacing combining three algorithms - (a) atrial antitachycardia pacing with Reactive ATP enabled, (b) atrial preventive pacing and (c) managed ventricular pacing (MVP)-may effectively delay progression to persistent/permanent AF compared with standard DDDR pacing. We performed a comparative non-randomised evaluation to evaluate if Reactive ATP can be the main driver of persistent/permanent AF reduction independently on preventive pacing. METHODS: Thirty-one centres included consecutive dual-chamber pacemaker patients with AF history. Reactive ATP was programmed in all patients while preventive atrial pacing was not enabled. These patients were compared with the three groups of MINERVA randomised trial (Control DDDR, MVP, and DDDRP). The main endpoint was the incidence of AF longer than 7 consecutive days. RESULTS: A total of 146 patients (73 years old, 54% male) were included and followed for a median observation period of 31 months. The 2-year incidence of AF > 7 days was 12% in the Reactive ATP group, very similar to that found in the DDDRP arm of the MINERVA trial (13.8%, P = .732) and significantly lower than AF incidence found in the MINERVA Control DDDR arm (25.8%, P = .012) and in the MINERVA MVP arm (25.9%, P = .025). CONCLUSIONS: In a real-world population of dual-chamber pacemaker patients with AF history, the use of Reactive ATP is associated with a low incidence of persistent AF, highlighting that the positive results of the MINERVA trial were related to the effectiveness of Reactive ATP rather than to preventive pacing.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2020) conducted an observational in Atrial fibrillation (n=146). Reactive ATP vs. Standard DDDR pacing (MINERVA Control DDDR arm) was evaluated on Incidence of AF longer than 7 consecutive days (p=0.012). Reactive ATP programming in pacemaker patients with atrial fibrillation history was associated with a lower 2-year incidence of persistent AF compared to standard DDDR pacing.
Synapse has enriched 10 related papers. Consider them for comparative context: